Mirae Asset Global Investments Co. Ltd. Raises Position in Regeneron Pharmaceuticals, Inc. $REGN

Mirae Asset Global Investments Co. Ltd. increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,166 shares of the biopharmaceutical company’s stock after purchasing an additional 4,080 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $30,012,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. E Fund Management Hong Kong Co. Ltd. raised its position in Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management raised its position in Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 21 shares during the period. Costello Asset Management INC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth $27,000. Saudi Central Bank purchased a new position in Regeneron Pharmaceuticals in the 1st quarter worth $27,000. Finally, Curat Global LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $32,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of research firms have issued reports on REGN. Rothschild & Co Redburn initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a “buy” rating and a $890.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, September 27th. Sanford C. Bernstein increased their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an “overweight” rating on the stock in a research note on Monday, June 9th. Finally, Argus lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, June 30th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $817.67.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $600.00 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm’s 50-day moving average price is $572.12 and its 200-day moving average price is $567.94. The company has a market capitalization of $63.59 billion, a PE ratio of 15.12, a P/E/G ratio of 1.92 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,024.36.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to analysts’ expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Regeneron Pharmaceuticals’s revenue was up 3.6% on a year-over-year basis. During the same period last year, the company posted $11.56 EPS. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.